...
首页> 外文期刊>Biochimica et biophysica acta. Molecular cell research >Elabela/toddler: New peptide with a promising future in cancer diagnostic and therapy
【24h】

Elabela/toddler: New peptide with a promising future in cancer diagnostic and therapy

机译:Elabela / Toddler:癌症诊断和治疗的未来未来的新肽

获取原文
获取原文并翻译 | 示例

摘要

Elabela/toddler is the second endogenous ligand recently identified after Apelin, that binds to the G protein-coupled receptor APJ. Elabela is a 54-amino acid peptide initially identified in fish and human genomes and classified as noncoding. This precursor can be cleaved to shorter sequences (32, 21, and 11 amino acids), which bind and activate APJ, and can be blocked by APJ antagonists. Contrary to Apelin and APJ, widely distributed in organs and tissues, Elabela expression is more restricted, and different studies have revealed the potential role of Elabela in cancers. This review summarizes the current studies focusing on the role of Elabela in different cancers.
机译:Elabela /幼儿是最近在阿贝林后最近鉴定的第二内源性配体,其与G蛋白偶联受体APJ结合。 Elabela是最初在鱼类和人类基因组中鉴定的54-氨基酸肽,并将其分类为非编码。 该前体可以切割为较短的序列(32,21和11个氨基酸),其结合和激活APJ,可以通过APJ拮抗剂阻断。 与阿糖素和APJ相反,广泛分布在器官和组织中,Elabela表达更受限制,不同的研究表明Elabela在癌症中的潜在作用。 本综述总结了目前的研究,重点是elabela在不同癌症中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号